Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints president of global pharmaceuticals

Luke Miels joins from AstraZeneca

GlaxoSmithKline Luke MielsGlaxoSmithKline has appointed Luke Miels as president of global pharmaceuticals, succeeding Abbas Hussain.

Miels joins the UK-headquartered firm from AstraZeneca, where he is currently executive vice president of AZ's European business. Prior to this, Miels served as executive vice president of global product and portfolio strategy, global medical affairs and corporate affairs.

He moved to AZ from Roche in 2014, having been regional vice president of its Asia-Pacific pharmaceutical operations, based in Shanghai, Singapore, after promotion from vice president and head of metabolism and anemia global marketing for Roche Switzerland.

He also brings management experience from Sanofi's operations in the US, Thailand, New Zealand and Australia to the role.

Emma Walmsley, GSK's chief executive officer designate, said: “Luke brings a combination of excellent R&D insight and a strong track record of commercial execution.

“We are now entering a critical period of commercialisation for our new pharmaceutical products and, over the next two to three years, we have important data to come on our early-stage pipeline.

“Luke will bring a strong new voice to the decisions and choices we will have to make for our pharmaceuticals business. I am delighted he has agreed to join GSK and look forward to welcoming him to the executive team.”

26th January 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics